These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31718106)

  • 1. A Pill in the Lifeworld of Women in Burkina Faso: Can Misoprostol Reframe the Meaning of Abortion.
    Drabo S
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31718106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abortion in two francophone African countries: a study of whether women have begun to use misoprostol in Benin and Burkina Faso.
    Baxerres C; Boko I; Konkobo A; Ouattara F; Guillaume A
    Contraception; 2018 Feb; 97(2):130-136. PubMed ID: 29104024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women's abortion seeking behavior under restrictive abortion laws in Mexico.
    Juarez F; Bankole A; Palma JL
    PLoS One; 2019; 14(12):e0226522. PubMed ID: 31881041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for postabortion care? Results from a randomised trial in Burkina Faso, West Africa.
    Dao B; Blum J; Thieba B; Raghavan S; Ouedraego M; Lankoande J; Winikoff B
    BJOG; 2007 Nov; 114(11):1368-75. PubMed ID: 17803715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motivations for using misoprostol for abortion outside the formal healthcare system in Colombia: a qualitative study of women seeking postabortion care in Bogotá and the Coffee Axis.
    Ortiz J; Blades N; Prada E
    Reprod Health; 2024 Jun; 21(1):76. PubMed ID: 38824533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitating women's access to misoprostol through community-based advocacy in Kenya and Tanzania.
    Coeytaux F; Hessini L; Ejano N; Obbuyi A; Oguttu M; Osur J; Shuken K
    Int J Gynaecol Obstet; 2014 Apr; 125(1):53-5. PubMed ID: 24447412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opening a door to safe abortion: international perspectives on medical abortifacient use.
    Pollack AE; Pine RN
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):186-8. PubMed ID: 10846335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconceptualizing safe abortion and abortion services in the age of abortion pills: A discussion paper.
    Berer M
    Best Pract Res Clin Obstet Gynaecol; 2020 Feb; 63():45-55. PubMed ID: 31494046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsafe abortion requiring hospital admission in the Eastern Highlands of Papua New Guinea--a descriptive study of women's and health care workers' experiences.
    Vallely LM; Homiehombo P; Kelly-Hanku A; Whittaker A
    Reprod Health; 2015 Mar; 12():22. PubMed ID: 25889957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commercial availability of misoprostol and induced abortion in Brazil.
    Costa SH
    Int J Gynaecol Obstet; 1998 Dec; 63 Suppl 1():S131-9. PubMed ID: 10075223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
    Schaff EA; Eisinger SH; Stadalius LS; Franks P; Gore BZ; Poppema S
    Contraception; 1999 Jan; 59(1):1-6. PubMed ID: 10342079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
    Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
    Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population.
    Rosing MA; Archbald CD
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):183-5. PubMed ID: 10846334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an intervention initiated by a national society to improve postabortion care in rural facilities in Burkina Faso.
    Kiemtoré S; Zamané H; Kaïn DP; Sawadogo YA; Ouédraogo I; Ouédraogo A; Lankoandé J
    Int J Gynaecol Obstet; 2017 Feb; 136(2):215-219. PubMed ID: 28099728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual [corrected] misoprostol as first-line care for incomplete abortion in Burkina Faso.
    Blandine T; Ouattara AZ; Coral A; Hassane C; Clotaire H; Dao B; Lankoande J; Diop A; Blum J
    Int J Gynaecol Obstet; 2012 Nov; 119(2):166-9. PubMed ID: 22935621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol.
    Elul B; Pearlman E; Sorhaindo A; Simonds W; Westhoff C
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):169-72. PubMed ID: 10846331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Misoprostol alone for early medical abortion in a Latin American clinic setting.
    Billings DL
    Reprod Health Matters; 2004 Nov; 12(24 Suppl):57-64. PubMed ID: 15938158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013.
    Løkeland M; Bjørge T; Iversen OE; Akerkar R; Bjørge L
    Int J Epidemiol; 2017 Apr; 46(2):643-651. PubMed ID: 28031316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Women's experiences with the use of medical abortion in a legally restricted context: the case of Argentina.
    Ramos S; Romero M; Aizenberg L
    Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):4-15. PubMed ID: 25702064
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.